Background: Excessive ethanol (EtOH) consumption remains an important health concern and effective treatments are lacking. The central oxytocin system has emerged as a potentially important therapeutic target for alcohol and drug addiction. These studies tested the hypothesis that oxytocin reduces EtOH consumption.
O
XYTOCIN IS AN endogenous neurohormone synthesized in the paraventricular nucleus (PVN) and supraoptic nucleus of the hypothalamus and released by the posterior pituitary into peripheral circulation. In addition, oxytocin is released by neurons in the PVN that project to numerous extrahypothalamic regions in the brain (e.g., cortical, limbic, basal ganglia structures) where it mediates an array of behavioral effects via interaction with G(q)-coupled oxytocin receptors . Aside from its known hormonal role in parturition and maternal behaviors, oxytocin also regulates a number of behaviors that involve social interactions (e.g., pair-bonding, social reward processing, aggression) and nonsocial behaviors, including anxiety and stress responses (Baskerville and Douglas, 2010; Bowen et al., 2011; Carson et al., 2013; Neumann and Landgraf, 2012) .
A growing body of literature suggests that oxytocin plays a role in several neuropsychiatric disorders that involve deficits in social behaviors, including drug and alcohol addiction (Baskerville and Douglas, 2010; Lee and Weerts, 2016) . For example, while alcohol use initially promotes prosocial behaviors, continued excessive drinking can lead to longterm social deficits associated with alcohol dependence, a negative consequence that may be mediated, at least in part, by adaptations in the oxytocin system (McGregor and Bowen, 2012; Stauffer and Woolley, 2014; Young et al., 2014) . In a recent clinical study, Pedersen and colleagues (2013) demonstrated that intranasal oxytocin treatment attenuated alcohol withdrawal symptoms in treatment-seeking human subjects compared to placebo. Further, a number of preclinical studies provide support for a role of oxytocin in modulating alcohol preference and consumption. In a recent study, oxytocin was shown to reduce operant responding for alcohol in Sprague Dawley rats (MacFadyen et al., 2016) . Acute oxytocin treatment also produced a significant and lasting decrease in preference for an alcohol-containing solution versus a nonalcoholic sucrose solution in alcoholpreferring "P" rats (McGregor and Bowen, 2012) . Additionally, Bowen and colleagues (2011) demonstrated that chronic exposure to exogenous oxytocin in adolescence decreased alcohol consumption in adult rats. Thus, administration of exogenous oxytocin has been shown to alter a number of alcohol effects, including its motivational effects.
Many of the oxytocin PVN projections in brain overlap with dopamine systems critically involved in processing motivationally relevant stimuli. An emerging literature suggests that oxytocin can alter dopaminergic neurotransmission within mesocorticolimbic dopamine systems, thereby altering motivational aspects of not only social and maternal behavior, but also alcohol/drug addiction (Baskerville and Douglas, 2010; Burkett and Young, 2012; Groppe et al., 2013; Love, 2014) . For example, direct (intracerebroventricular [icv.]) infusion of oxytocin blocked alcohol-induced increases in dopamine release in the nucleus accumbens and reduced voluntary alcohol consumption in Wistar rats (Peters et al., 2016) . Additionally, viral-mediated overexpression of oxytocin receptors in the nucleus accumbens reduced alcohol-induced conditioned place preference and alcohol consumption in C57BL/6J mice (Bahi, 2015; Bahi et al., 2016) . Taken together, accumulating evidence suggests that the oxytocin system may represent a promising target for the treatment of alcohol use disorders (Lee and Weerts, 2016; .
However, few studies have examined the broad efficacy and specificity of systemically administered oxytocin in reducing voluntary ethanol (EtOH) consumption, and whether oxytocin influences the motivational effects of EtOH. In the present study, we investigated the effects of systemic administration of oxytocin on EtOH self-administration in a binge-like drinking model, in a 2-bottle choice paradigm, and in a model involving operant conditioning procedures. Specificity of oxytocin effects in the operant studies were examined by conducting parallel studies with sucrose solutions. It was hypothesized that oxytocin would selectively decrease EtOH consumption in these models at doses that would not affect sucrose consumption under similar testing conditions.
MATERIALS AND METHODS

Subjects
Adult male C57BL/6J mice (25 to 30 g) were obtained from Jackson Laboratories (Bar Harbor, ME). Mice arrived at 9 to 10 weeks of age and were acclimated to the experimental housing rooms for a minimum of 1 week prior to the start of experiments. Mice were individually housed under a 12-hour reversed light/dark cycle in an AAALAC-accredited facility. All testing was conducted during the dark phase of the circadian cycle. Mice were provided free access to food and water, except at the start of operant oral self-administration training. All experimental protocols were approved by the Medical University of South Carolina Institutional Animal Care and Use Committee and consistent with guidelines of the NIH Guide for the Care and Use of Laboratory Animals.
Binge-Like EtOH Consumption
The effect of oxytocin (OT) on binge-like EtOH consumption was examined in C57BL/6J mice (n = 40) using the drinking-inthe-dark (DID) paradigm (Rhodes et al., 2005) . Mice were presented in the home cage with a single 15-ml graduated bottle of 20% (v/v) EtOH 3 hours into the dark phase of the circadian light cycle. Mice were provided access to EtOH for 2 h/d for 3 consecutive days. On the fourth day, access to EtOH was extended to 4 hours. Vehicle injections were given 30 minutes prior to the 2-hour drinking sessions during the first 3 days to acclimate mice to handling and the injection procedure. On day 4, separate groups of mice were injected intraperitoneally (ip.) with OT (0, 1, 3, or 10 mg/kg) 30 minutes prior to the 4-hour drinking session. These OT doses and the route of administration were selected based on previous work in rodents (e.g., Bahi, 2015; Bowen et al., 2011; McGregor and Bowen, 2012; Peters et al., 2013) . Immediately following this test session, blood samples were collected to measure blood EtOH concentration (BEC) using an Analox Instrument analyzer (Lunenburg, MA).
As results from the previous study indicated that the 3 and 10 mg/kg doses of OT were similarly efficacious in reducing alcohol consumption, a follow-up study was conducted to extend these findings to a lower dose range for OT. Additionally, to assess the temporal distribution of EtOH consumption during the 4-hour session, a separate group of mice (n = 24) was tested in the DID model, with the EtOH bottles fitted with lickometers as previously described (Griffin et al., 2009 ). Briefly, contacts (i.e., "licks") with the EtOH tube completed a circuit grounded to the stainless steel grid floor inside of the home cage. The metal drinking spouts were covered with plastic shrink-wrap coating to limit extraneous contacts. The metal cage floor and tubes were connected through lickometer circuits (Med Associates, Inc., St. Albans, VT), and contacts were monitored and recorded by a computer outside of the testing room. Mice were acclimated to the lickometers in their home cage by providing drinking water (24 h/d) in bottles connected to the lickometer for 1 week prior to DID testing. As in the previous experiment, vehicle injections were given to all mice 30 minutes before the 2-hour drinking sessions and on the fourth day, separate groups of mice were injected (ip.) with OT (0, 0.3, 1, or 3 mg/kg) 30 minutes prior to the 4-hour test session.
Finally, to investigate whether exogenous oxytocin administration was exerting its effects on EtOH consumption in the DID model via actions at the oxytocin receptor, a separate cohort of mice (n = 40) was pretreated with the selective brain penetrant, nonpeptide oxytocin receptor antagonist L-368,899 (10 mg/kg) (Borthwick, 2010; Kuteykin-Teplyakov and Maldonado, 2014; Olszewski et al., 2013) , or vehicle (0.9% saline) 15 minutes prior to OT (1 mg/kg) or vehicle (saline) administration (ip.), which was given 30 minutes before the start of the 4-hour test drinking session.
Two-Bottle Choice EtOH Drinking
Mice (N = 12) were provided unlimited daily access to 2 drinking bottles in the home cage containing either 20% (v/v) EtOH or tap water. As OT has been reported to reduce general fluid intake in rats (Arletti et al., 1990) , a separate group of mice (N = 9) was given 2 bottles containing water throughout the study to assess potential effects of OT treatment on general water intake. The position of the bottles was alternated daily to avoid a side preference. Mice were weighed weekly and fluid intake was measured at 4 and 24 hours. After establishing stable daily EtOH and water intake over 3 weeks, half the mice in the EtOH versus water and water versus water groups were injected (ip.) with 1 mg/kg OT while the remaining mice in each group received a saline injection. Following an additional 3 days when all mice were treated with saline, mice were tested again with the alternative drug (1 mg/kg OT or saline). Data were collapsed across dose condition for analyses.
Locomotor Activity
Following the DID study involving use of lickometer circuitry, mice were left undisturbed for 4 weeks and then tested for effects of oxytocin on locomotor activity. The mice (n = 24) were injected (ip.) with the same doses of OT (0, 0.3, 1, or 3 mg/kg) 30 minutes before the start of the test session. Injections occurred 2.5 hours into the dark phase of the circadian cycle to match the DID procedure. Locomotor activity in an open-field arena was assessed using Med Associates activity chambers (27 9 27 9 20 cm; ENV-510) situated in sound-attenuating cubicles with a ventilation fan. Animal movement was tracked through the use of 16 horizontal infrared photobeams, located on both the X-and Y-axes for positional and rearing detection. Photobeam breaks were recorded and converted to distance traveled using activity-monitoring software (Activity Monitor 5.0; Med Associates).
Operant Self-Administration Operant Conditioning Chambers. Mice were tested in standard operant chambers configured with 2 retractable levers, a centrally located well for liquid reinforcers, house light, and a tone generator and stimulus light above the well. The chambers were situated in sound-attenuating cubicles with a ventilation fan (Med Associates). One lever was assigned as the "active" lever, with responses resulting in access to EtOH or sucrose reinforcement paired with a light and tone stimulus (80 dB). EtOH or sucrose reinforcement (20 ll) was delivered to the well by an infusion pump (activated for 2 seconds). Responses on the "inactive lever" were recorded, but did not result in any stimulus consequences or reinforcement delivery. Stimulus events and responses were controlled and monitored using Med PC, Version IV software (Med Associates). At the end of each session, any residual fluid left in the well was collected with a pipette, measured, and subtracted from the total volume of reinforcer delivered. The corrected volume was used to calculate g/kg EtOH or ml/kg sucrose intake during the sessions.
EtOH and Sucrose Self-Administration Procedure. Mice were trained to orally self-administer EtOH or sucrose using a postprandial consumption procedure to facilitate acquisition of the behavior. One hour prior to the beginning of initial self-administration sessions, water bottles were removed from the cages and mice were given access to standard home cage chow for 15 minutes. Water bottles were returned to the home cage following the conclusion of the behavioral session. During the postprandial manipulation (2 to 3 weeks), weights were monitored and food was provided after the behavioral session to maintain weight at 90 to 95% pretraining body weight. Mice were trained to respond on a fixed-ratio (FR)-1 schedule for access to 12% unsweetened EtOH or 5% sucrose solution in 20-minute sessions. Once mice acquired stable rates of responding, the response requirement was increased to FR2 and then FR4 over 1 to 3 weeks. When mice demonstrated stable responding on the FR4 schedule, they were returned to ad libitum food and water access for the remainder of the study. Experiments were initiated after response rates had stabilized (<15% variability over 3 consecutive days). To assess the effects of oxytocin administration on operant self-administration of EtOH (n = 13) or sucrose (n = 18), mice were injected (ip.) with different doses of OT (0, 0.1, 0.3, or 1 mg/kg) 30 minutes before self-administration sessions. Each mouse received all treatment conditions in a Latin square design, counterbalanced to avoid an order of treatment bias. Baseline levels of responding were re-established without drug pretreatment for a minimum of 3 days between treatments.
Progressive-Ratio Testing. The effect of oxytocin on motivation to seek EtOH or sucrose reward was assessed in a subset of the animals trained to self-administer EtOH (n = 10) or sucrose (n = 12) using a progressive -ratio (PR) paradigm. To avoid any residual drug effects, mice were left undisturbed in the home cage for 4 consecutive weeks prior to re-establishing baseline lever responding. After stable baseline (FR4) responding was re-established (<15% variability over 3 consecutive days), animals were tested on a PR schedule. Mice were injected (ip.) with either OT (0.3 mg/kg) or vehicle 30 minutes prior to testing using a crossover design over 2 test sessions spaced 7 days apart. The PR schedule followed an arithmetic series, with the response requirement to obtain EtOH or sucrose reinforcement increased by 4 (i.e., FR 4, 8, 12, 16, 20, etc.) . Breakpoint was defined as the highest ratio value reached during the session. The session was terminated following any 5-minute period of inactivity on the active lever. Maximum session length was 3 hours, at which point the session was terminated.
Drugs
Synthetic human oxytocin (CellSciences, Canton, MA) and the oxytocin receptor antagonist, L-368,899 hydrochloride (Tocris Bioscience, Minneapolis, MN), were dissolved in 0.9% saline, which served as the vehicle. Injections were administered intraperitoneally at a volume of 0.01 ml/g body weight in all experiments. EtOH (95%) was obtained from AAPER (Shelbyville, KY) and diluted with tap water to the appropriate concentration. Sucrose was also diluted to the appropriate concentration with tap water (5% w/v). The EtOH and sucrose solutions were prepared daily and presented at room temperature.
Statistical Analysis
Primary dependent variables were EtOH intake (g/kg), BEC (mg/ dl), sucrose intake (ml/kg), EtOH lick contacts, and distance traveled (cm) for the binge drinking studies. EtOH intake (ml; g/kg), water intake (ml), total fluid intake (ml), and EtOH preference ratio (24 hours) were analyzed in the 2-bottle choice EtOH drinking study. Dependent measures for the operant studies included lever responses and EtOH/sucrose intake, as well as breakpoints on the PR schedule. Data were analyzed by analysis of variance (ANOVA), with Dose as a between-subjects factor (DID model studies) or a within-subjects factor (2-bottle choice drinking and operant conditioning studies). The factor Time served as a repeated measure in analyses of lick responses and locomotor activity. Breakpoint data from PR testing were analyzed by t-tests. Further analyses were conducted using Newman-Keuls test, when appropriate. For all analyses, significance levels were set at p < 0.05, and data are presented as mean AE standard error of the mean (SEM).
RESULTS
Effect of Oxytocin on Binge-Like EtOH Consumption
Oxytocin significantly reduced EtOH consumption and resultant BECs in a dose-related manner. ANOVA revealed a significant effect of Dose, F(3, 36) = 12.31, p < 0.0001, on EtOH intake, and post hoc analysis indicated a significant decrease in consumption following 1, 3, and 10 mg/kg OT compared to vehicle (Fig. 1A) . Analysis of BEC data indicated a similar profile of results, with ANOVA indicating a significant effect of Dose, F(3, 36) = 4.86, p < 0.01. Further analysis indicated that 3 and 10 mg/kg OT doses significantly reduced BEC compared to the vehicle condition, with a trend for reduction at the 1 mg/kg dose (Fig. 1B) .
In a follow-up study with a separate cohort of mice, a lower OT dose range was examined on EtOH intake in the DID model. Additionally, lickometer circuitry was employed to examine the temporal pattern of EtOH intake in the study. As in the previous study, ANOVA revealed a significant effect of OT Dose, F(3, 19) = 35.18, p < 0.0001, on EtOH consumption during the 4-hour drinking session. Post hoc analysis revealed that 0.3, 1, and 3 mg/kg OT doses significantly decreased EtOH intake compared to the vehicle condition, and the 2 higher doses of OT were more effective than the lowest (0.3 mg/kg) OT dose in reducing EtOH intake ( Fig. 2A) . Further, OT administration decreased licking responses at the EtOH bottle in a dose-related manner (Fig. 2B) . Whereas mice treated with vehicle evidenced relatively consistent intake over the entire 4-hour session with cumulative licks increasing steadily over time, mice treated with OT exhibited significant delay in contact with the EtOH bottle, only beginning to drink 1 to 2 hours after bottles, were available. This was supported by ANOVA of the lick data, which revealed significant main effects of OT Dose, F(3, 18) = 30.88, p < 0.0001, and Time, F(23, 414) = 57.10, p < 0.0001, and a Dose 9 Time interaction, F(69, 414) = 5.03, p < 0.0001. Analysis of total cumulative lick responses indicated a significant effect of OT Dose, F(3, 18) = 14.39, p < 0.001, and post hoc analyses indicated that all 3 OT doses (0.3, 1, and 3 mg/kg) significantly decreased EtOH lick contacts compared to vehicle over the entire 4-hour drinking session. Further, there was a trend for the highest OT dose to reduce EtOH bottle contacts more than the 2 lower doses (p < 0.07).
Reversal of Oxytocin Effect on EtOH Consumption by an Oxytocin Receptor Antagonist
To determine whether OT reduced EtOH consumption via its receptor, separate groups of mice were treated with a selective OT receptor antagonist, L368,889, before OT or vehicle (saline) administration. As previously observed, OT (1 mg/kg) significantly reduced EtOH consumption in the DID model. However, this effect was blocked in animals that were pretreated with the OT receptor antagonist (Fig. 3) . These observations were supported by ANOVA, which revealed a significant main effect of OT Dose, F(1, 36) = 9.08, p < 0.005, and an OT 9 Antagonist interaction, F(1, 36) = 10.36, p < 0.003. Post hoc analysis indicated that OT alone significantly reduced EtOH intake and that EtOH intake was significantly greater in OT-treated mice that received L-368,889 (10 mg/kg) compared to mice that received saline pretreatment. The OT receptor antagonist did not alter EtOH consumption when given alone.
Effect of Oxytocin on Locomotor Activity
The reduction in EtOH consumption by OT in concert with the delayed temporal pattern of EtOH intake prompted additional examination of whether the OT-induced decrease in EtOH intake is due to a general sedative effect of the neurohormone. Within 5 minutes following administration, OT decreased locomotor activity in a dose-related manner. While this difference relative to the vehicle condition rapidly dissipated for the lower (0.3 and 1 mg/kg) OT dose groups, reduced activity produced by the highest dose tested (3 mg/ kg) persisted for a longer period of time during the test session (Fig. 4) . ANOVA of activity data (distance traveled in the open field) indicated significant main effects of Dose, F(3, 19) = 9.87, p < 0.0001, and Time, F(11, 209) = 12.76, p < 0.0001, as well as the Dose 9 Time interaction, F(33, 209) = 3.90, p < 0.0001. Overall, activity decreased across the testing session for all groups. Further, all OT doses significantly decreased distance traveled compared to the vehicle group within the first 5 minutes of the test. However, while activity for mice treated with 0.3 and 1 mg/kg OT doses was similar to the vehicle group within 10 minutes, recovery to control (vehicle) levels required approximately 40 to 45 minutes for mice treated with 3 mg/kg OT.
Effect of Oxytocin on 2-Bottle Choice EtOH Drinking
Oxytocin treatment reduced EtOH consumption without significantly altering total fluid intake under continuous access conditions (Table 1) . At 4 hours following injection, OT (1 mg/kg) significantly reduced EtOH intake, ml: F(1, 11) = 5.92, p < 0.05, and g/kg: F(1, 11) = 6.16, p < 0.05, while not altering total fluid intake, F(1, 11) < 1.0. Similarly, OT (1 mg/kg) reduced EtOH intake over 24 hours, ml: F(1, 11) = 20.39, p < 0.001, and g/kg: F(1, 11) = 20.87, p < 0.001. The decrease in EtOH consumption was accompanied by increased water intake, F(1, 11) = 6.51, p < 0.05, resulting in no change in total fluid intake, F(1, 11) < 1.0. OT treatment also significantly reduced EtOH preference, F(1, 11) = 12.80, p < 0.01 (Table 1) . In animals given access to only water, OT did not alter intake at 4 hours, F(1, 8) = 1.37, p > 0.1 or 24 hours F(1, 8) = 0.07, p > 0.1.
Effect of Oxytocin on Operant EtOH Self-Administration
After reaching the criteria for stable responding for EtOH, the effect of OT on operant oral self-administration was assessed. For these studies, we omitted the higher doses (3 and 10 mg/kg) from the previous experiments and included a lower dose (0.1 mg/kg) of OT. Preliminary analyses indicated no significant effect of dosing order on the main dependent variables: active lever responses and EtOH (g/kg) intake, F(5, 46) < 1.6 for both variables. Thus, data were collapsed across this variable to analyze OT effects on EtOH self-administration behavior.
In a dose-related fashion, OT reduced responding for EtOH on the active lever (Fig. 5A ) and the amount of EtOH (g/kg) self-administered (Fig. 5B) . These observations were supported by significant effects of OT Dose for active lever responding, F(3, 36) = 7.58, p < 0.001, and EtOH intake, F(3, 36) = 8.41, p < 0.001. Post hoc analyses indicated that all doses of OT significantly reduced EtOH responding and intake compared to the vehicle condition. Analysis of inactive lever responding indicated no significant effect of OT Dose (Fig. 5A) .
To investigate the effect of OT on motivation to seek EtOH reinforcement, a subset of the same mice (n = 10) were challenged using a PR self-administration schedule. OT decreased overall active lever responding during the PR sessions. Further, analysis of breakpoint data indicated that OT (0.3 mg/kg) significantly reduced breakpoint ratio achieved for EtOH reward compared to vehicle, t(8) = 2.82, p < 0.03 (Fig. 6 ).
Effect of Oxytocin on Sucrose Self-Administration
To investigate whether OT administration influences selfadministration of a natural reward, a separate cohort of mice was trained to respond for sucrose reinforcement. One mouse was excluded from the final analysis due to receiving incorrect doses in the Latin square design. Preliminary analyses indicated that dosing order did not have a significant effect on active lever responding or ml/kg sucrose intake, F(4, 66) < 2.4 for both dependent measures. However, ANOVA revealed a marginal OT Dose effect on active lever responding, F(3, 51) = 2.48, p < 0.07 (Fig. 7A) , and a significant effect on ml/kg intake, F(3, 51) = 3.33, p < 0.05 (Fig. 7B) . Post hoc analysis revealed that the highest dose of OT (1 mg/kg) significantly reduced ml/kg intake of sucrose compared to vehicle. OT treatment did not significantly alter inactive lever responding (Fig. 7A) .
A subset of mice (n = 12) from the sucrose self-administration experiment were then tested for responding under a PR schedule. OT (0.3 mg/kg) did not significantly alter responding for sucrose during PR sessions, and analysis of breakpoint data indicated no significant difference between OT and vehicle conditions, t(10) = 1.31, p > 0.20 (Fig. 8) .
DISCUSSION
Results from the present study demonstrate that systemic administration of oxytocin reduces EtOH consumption in a binge-like drinking model, 2-bottle choice drinking paradigm, and in a model that employs operant self-administration procedures (Table 2) . Oxytocin decreased EtOH consumption in a dose-related manner, and the ability of oxytocin to reduce EtOH intake did not appear to be related to nonspecific (e.g., sedation, antidipsogenic) effects. Further, oxytocin reduced motivation to respond for EtOH at doses that did not alter responding for a natural reward (sucrose). These results are generally consistent with other reports indicating that systemic administration of oxytocin reduces EtOH intake in a variety of drinking models in rats (Bowen et al., 2011; MacFadyen et al., 2016; McGregor and Bowen, 2012 ) and mice (Peters et al., 2013) . These data also complement a recent report showing that direct (icv.) infusion of the neuropeptide reduced EtOH consumption in Wistar rats (Peters et al., 2016) .
Active
Oxytocin reduced relatively high levels of EtOH intake along with resultant BECs in the binge-like DID model. Use of lickometers provided an opportunity to analyze the effects of oxytocin on the temporal pattern of EtOH drinking during the final (fourth day) of the DID procedure. Results showed vehicle-treated mice initiated licking contacts at the EtOH bottle within the first 5 to 10 minutes of the drinking period and maintained a relatively steady pace of drinking throughout the entire 4-hour session. In contrast, oxytocin treatment delayed EtOH bottle contacts until 1 to 2 hours into the session. This profile suggests oxytocin reduced motivation to seek and consume EtOH under these testing conditions.
Alternatively, the delay in initiating drinking produced by oxytocin could be due to a sedative effect of the neuropeptide. Oxytocin has been shown to reduce locomotor activity in rats (Klenerova et al., 2009; Uvnas-Moberg et al., 1994; Zhou et al., 2015) . In the present study, oxytocin reduced locomotor activity in an open field in a dose-related manner. However, this effect was transient, with activity returning to levels registered in vehicle-treated mice within 10 minutes for mice treated with low doses of oxytocin (0.3 and 1 mg/kg). In contrast, reduced activity produced by a high oxytocin dose (3 mg/kg) did not recover to control levels until at least 40 to 45 minutes into the test session. These results are congruent with other reports indicating that low-dose anxiolytic effects of oxytocin can be distinguished from sedative effects produced by higher doses of the neuropeptide (Bahi et al., 2016; Klenerova et al., 2009 (Bowen et al., 2015) . Taken together, it does not seem likely that the reduction in EtOH drinking produced by low doses of oxytocin can be simply attributed to a nonspecific sedative effect of the neuropeptide. Additionally, while oxytocin has been reported to produce an antidipsogenic effect in rats (Arletti et al., 1990) , in the present study, oxytocin did not alter general fluid intake. In fact, reduced EtOH consumption was compensated by increased water intake. Further, in mice offered only water, oxytocin treatment did not alter total fluid intake. Thus, it is unlikely that reduced EtOH consumption in the various drinking models can be simply attributed to oxytocin decreasing general fluid intake. Using operant conditioning procedures, oxytocin was shown to reduce EtOH responding and intake in a doserelated fashion. Moreover, this effect was produced at doses that did not alter self-administration of a natural reward (sucrose). The highest oxytocin dose tested in these operant selfadministration studies (1 mg/kg) reduced responding for both EtOH and sucrose. Other studies have shown oxytocin given either systemically or centrally (infused into the ventral tegmental area) reduced sucrose intake in rats (Mullis et al., 2013; Zhou et al., 2015) . While the present studies were conducted in only male mice, there is some evidence that females may be more sensitive than males to the supressant effects of oxytocin on sucrose consumption (Zhou et al., 2015) . Nevertheless, it is noteworthy that in the present study, low doses of oxytocin reduced EtOH responding and intake without altering sucrose self-administration. The fact that responding on an "inactive" lever in both EtOH and sucrose experiments was not significantly altered by oxytocin also supports the notion that reduced EtOH self-administration is not related to a general sedative effect of the neuropeptide.
Results from PR testing further support a selective effect of oxytocin in decreasing motivation to self-administer EtOH. Oxytocin (0.3 mg/kg) reduced breakpoint value for EtOH while not altering this measure for sucrose. Similarly, a recent study in rats showed 1 mg/kg oxytocin did not alter PR responding or breakpoint for sucrose pellets (Cox et al., 2013) . While it is possible that higher doses of oxytocin may reduce motivation to respond for a natural reward, results from the present study demonstrate that at a low dose, oxytocin can selectively reduce responding for EtOH. Collectively, these results align with a growing body of literature demonstrating efficacy for oxytocin to reduce alcohol/drug seeking and consumption .
The mechanism by which systemically administered oxytocin reduces EtOH consumption is not fully understood. Peripheral administration (ip. injection) of oxytocin was shown to produce a rapid rise in plasma and brain dialysate levels of oxytocin in mice . While penetration of the neuropeptide through the blood-brain barrier is limited, passage of a small, yet physiologically relevant amount of exogenous oxytocin is thought to influence central oxytocin activity (Landgraf and Neumann, 2004; Neumann and Landgraf, 2012; Neumann et al., 2013) . There is evidence indicating that oxytocin can facilitate its own release in the hypothalamus (Moos et al., 1984; Rossoni et al., 2008; Theodosis, 2002) . This feed-forward loop may explain, at least in part, how acute and chronic systemically administered oxytocin can produce enduring functional and behavioral effects. For example, Bowen and colleagues (2011) showed that repeated injections of oxytocin in adolescent rats resulted in up-regulated oxytocin receptor mRNA expression in the hypothalamus in adult rats, which was accompanied by reduced EtOH consumption. Nevertheless, whether reduced EtOH intake produced by systemic administration of oxytocin in the present studies can be attributed to direct effects of the exogenous neuropeptide in the brain or indirect effects on release of endogenous oxytocin in brain is unknown and will require further investigation.
Oxytocin projections are known to influence mesolimbic dopamine activity in mediating the rewarding aspects of social behaviors (Young et al., 2014) . The relatively high expression of oxytocin receptors within structures such as the nucleus accumbens suggests that modulation of mesolimbic dopamine pathways may underlie the ability of oxytocin to influence the rewarding effects of alcohol and other substances of abuse. In a recent study, direct (icv.) administration of oxytocin reduced EtOH consumption and EtOH-induced dopamine efflux in the nucleus accumbens of Wistar rats (Peters et al., 2016) . Thus, it is possible that oxytocin reduced EtOH self-administration in the present study by blunting mesolimbic dopamine activity that ordinarily signals EtOH-related reward.
In the present study, the ability of oxytocin to reduce binge-like drinking was blocked by pretreatment with an oxytocin receptor antagonist, suggesting that oxytocin reduced EtOH consumption via an interaction with its receptor. Few studies have examined the role of oxytocin receptors in mediating the neuropeptide's effects on motivational actions of alcohol. Recent studies involving viral-mediated overexpression of oxytocin receptors in the nucleus accumbens core have implicated a role for these receptors in EtOH drinking and conditioned reward (Bahi, 2015; Bahi et al., 2016) . However, it is noteworthy that oxytocin was shown to block EtOH-induced ataxic and sedative/hypnotic effects via an apparent direct interaction with delta-subunit containing GABA-A receptors (Bowen et al., 2015) . Thus, there remains some ambiguity as to the role of oxytocin receptors in mediating the neuropeptide's effects on physiological effects of EtOH and, in particular, EtOH-related reward and self-administration behavior.
Differing by only 2 amino acids from the related nonapeptide arginine vasopressin, it is possible that oxytocin reduced the motivational effects of EtOH through actions at vasopressin receptors (Neumann and Landgraf, 2012) . The 2 hypophyseal neuropeptide systems generally produce opposing physiological actions. Interestingly, the arginine vasopressin 1b (V1b) receptor antagonist SR149415 was shown to reduce EtOH drinking in genetically high alcohol-preferring rats (Zhou et al., 2011) and dependent Wistar rats (Edwards et al., 2012) . However, results from a study demonstrating that the synthetic oxytocin receptor agonist carbetocin, which exhibits low affinity for V1b (and V1a) receptors compared to oxytocin receptors (Passoni et al., 2016) , effectively reduced EtOH-induced conditioned reward supports a role for oxytocin receptors (Bahi, 2015) . Further investigation is needed to determine the relative role of these related neuropeptide receptors in mediating the ability of oxytocin to reduce EtOH reward and drinking.
In summary, results from this study provide support and extend evidence demonstrating the ability of oxytocin to reduce the motivational effects of EtOH. The present results indicate oxytocin is effective in reducing EtOH consumption in a model of binge-like drinking, an effect reversed by pretreatment with an oxytocin receptor antagonist. Oxytocin also decreased 2-bottle choice drinking in the home cage as well as EtOH responding and intake in an oral self-administration model involving operant conditioning procedures. Further, oxytocin reduced responding for EtOH under FR and PR schedules at doses that did not alter responding for a natural reward (sucrose). Collectively, these and other recent reports provide support for the therapeutic potential of this neuropeptide as a treatment for alcohol use disorders. A limited number of clinical studies have shown oxytocin to have some efficacy in decreasing craving for alcohol and other drugs of abuse . For example, Pedersen and colleagues (2013) recently demonstrated that intranasal oxytocin attenuated alcohol withdrawal symptoms in treatmentseeking human subjects compared to placebo. Thus, the oxytocin system may be a promising target for therapeutic intervention of alcohol use disorders, although additional studies are necessary to establish its clinical efficacy and further investigate the conditions and mechanisms by which oxytocin reduces alcohol consumption.
